Early Screening and Treatment of Heart Complication in Sickle Cell Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT07023666

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07023666
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07023666. Allocation not applicable; no masking; primary purpose treatment. Start 2025-10-07 (actual); primary completion 2027-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Early Screening and Treatment of Heart Complication in Sickle Cell Disease
Condition
Sickle Cell Disease
Intervention (Drug)
Deferoxamine
Intervention (Drug)
Deferasirox
Intervention (Drug)
Deferiprone
Intervention (Device)
Echocardiography
Intervention (Device)
Electrocardiogram (ECG (electrocardiogram))
Lead sponsor
Inova Health Care Services (class: other)

Record details

Record id
cardio:ct-nct07023666
Content hash
5cf4a9cf813ab559cebeb7120b12f19bd6bd1b27be404ed07272b075e934d409